Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET
|
Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
Aegis Sciences Announces CDC Contract to Provide Genomic Sequencing of SARS-CoV-2 to Aid Public Health Response to COVID-19
March 16, 2021 09:00 ET
|
Aegis Sciences Corporation
NASHVILLE, Tenn., March 16, 2021 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative COVID-19 and medication compliance testing services,...
Aegis Sciences Corporation announces it has been awarded $6.6 million NIH grant to rapidly expand COVID-19 Test Capacity
September 02, 2020 11:05 ET
|
Aegis Sciences Corporation
NASHVILLE, Tenn., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting...
Aegis Sciences Corporation Announces National Launch of COVID-19 Antibody Testing Utilizing Convenient Dry Blood Spot Technology
August 31, 2020 10:30 ET
|
Aegis Sciences Corporation
NASHVILLE, Tenn., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services...
WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin
April 24, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
March 24, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces it has...
WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial
February 20, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide...
CURE Pharmaceutical [OTCQB: CURR] Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms
August 21, 2019 07:25 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp...
CURE Pharmaceutical Expands Board with Two Women Directors
August 07, 2019 07:25 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board,...